AllSci News
Alar's ketamine therapy meets safety goals in treatment-resistant depression Phase I
Alar Pharmaceuticals, a Taiwan-based clinical-stage company listed on the TPEx exchange, reported Phase I results for ALA-3000, a subcutaneous...
Apnimed preparing for sleep apnea drug approval with USD 150m debt, royalty deal
Cambridge, Massachusetts-based Apnimed, Inc. has secured up to USD 150 million in debt financing from HealthCare Royalty Partners to support commercial...
Ideaya's KAT6/7 inhibitor enters Phase I for breast, prostate, colorectal, and lung cancer
IDEAYA Biosciences announced on April 6 that the first patient has been dosed in a Phase I dose-escalation trial of IDE574, an oral small molecule designed...
Esperion closes deal for Corstasis Therapeutics' Enbumyst and CVD franchise
Esperion Therapeutics Expands Cardiovascular Franchise via Acquisition of Corstasis Therapeutics and FDA-Approved Enbumyst
Pillar Biosciences, CellCarta partner on decentralized NGS tumor profiling for oncology trials
Pillar Biosciences' oncoReveal® NGS panel portfolio sits at the center of a multi-year global strategic partnership with CellCarta, a Montreal-based...
Celldex Therapeutics raises USD 345m in stock offering
US-based Celldex Therapeutics, Inc. (Nasdaq: CLDX) announced the closing of an underwritten public offering of common stock on April 6, 2026, raising USD...
OneCyte and Kemp Proteins partner on integrated cell line development for biologics
OneCyte and Kemp Proteins announced a strategic partnership on April 3, 2026, combining their respective platform technologies to deliver integrated cell line…
Amgen's subcutaneous Tepezza meets primary endpoint in Phase III thyroid eye disease trial
Amgen (NASDAQ: AMGN) reported that a Phase III trial of subcutaneous teprotumumab-trbw (Tepezza) delivered via an on-body injector met its primary endpoint...
Quantum Bio filed IND for Lucid-MS to start Phase II in multiple sclerosis
Quantum BioPharma submitted an IND application to the U.S. Food and Drug Administration in March 2026 for Lucid-21-302, known as Lucid-MS, a small-molecule...
Opus Genetics secures USD 155m non-dilutive financing from Oberland Capital Management
Opus Genetics (NASDAQ: IRD), a clinical-stage gene therapy company focused on inherited retinal diseases and headquartered in Research Triangle Park, North...
Neurocrine expands rare disease portfolio via USD 2.9b acquisition of Soleno Therapeutics
Neurocrine Biosciences Expands Rare Disease Portfolio via USD 2.9 Billion Acquisition of Soleno Therapeutics
Stipple Bio closes USD 100m Series A financing for ADC pipeline
Cambridge, Massachusetts-based Stipple Bio, Inc., a private biotechnology company developing epitope-targeted cancer therapies, has closed a USD 100 million...
Pegasus Biotech and VIDO collaborate to advance plasma DNA platform
Canada-based Contract Research Organization (CRO) Pegasus Biotech Inc., announced a strategic collaboration with the Vaccine and Infectious Disease Organization (VIDO) at the…
FDA accepts Ultragenyx's UX111 gene therapy resubmission for Sanfilippo syndrome Type A treatment
Ultragenyx Pharmaceutical has submitted a resubmitted Biologics License Application to the US FDA for UX111 (rebisufligene etisparvovec), an AAV9 gene...
Immunome's 177Lu-IM-3050 enters Phase I trial targeting fibroblast activation protein-alpha
Immunome, Inc. has registered a first-in-human Phase 1 clinical trial for 177Lu-IM-3050, a lutetium-177-labeled radioligand targeting fibroblast activation...
The AllSci Brief
Systematic R&D and deal news. Daily.